This comprehensive assessment, which evaluated our entire organization and all functions, underscores our commitment to excellence in cybersecurity and risk management. CyberVadis is a leading global provider of independent cybersecurity assessment services, and their rigorous evaluation process includes international standards such as ISO 2700x, NIST Cybersecurity Framework, ICS Cybersecurity, and GDPR.
With an overall score of 868/1000, Biointron has been rated as mature. The overall CyberVadis benchmark score is 654/1000, and Biointron has surpassed all focus area and function scores of the average score from other assessed companies. The assessment demonstrates our perfect score of 1000 for 3rd party security management, which involves monitoring and managing the security risks associated with external vendors, partners, or service providers that have access to a company's data or systems. We also have mature scores for data privacy and data protection.
🔍 Why is this important for you?
A third-party cyber security risk assessment evaluates security practices to identify potential vulnerabilities that could pose a threat to an organization. This process involves reviewing the third party's policies, controls, and procedures to ensure they align with industry standards and regulatory requirements. By conducting such assessments, organizations can mitigate risks associated with data breaches, non-compliance, and operational disruptions, thereby safeguarding their sensitive information and maintaining the integrity of their cybersecurity posture.
The CyberVadis assessment helps streamline due diligence on third-party vendors, significantly reducing the risk of data breaches. In fact, a 2019 IBM and Ponemon Institute study found that 56% of organizations have faced data breaches caused by vendors.
At Biointron, we are dedicated to protecting our clients’ information through robust security management processes. Our adherence to a certified ISO 9001:2015 quality management system and our successful completion of cybersecurity assessments reflect our unwavering commitment to your security and trust.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
